- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1513–1536
of 17,150
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Coronary Syndrome
- Interventions
- Darapladib 160 mg, Placebo, Standard Therapy
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13,026 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 290
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 252 more
- Conditions
- Persistent Post-concussive Symptoms, Convergence Insufficiency, Mild Traumatic Brain Injury, Concussion, Mild, Concussion; Eye
- Interventions
- Office-based Vergence and Accommodative Therapy
- Behavioral
- Lead sponsor
- New Jersey Institute of Technology
- Other
- Eligibility
- 11 Years to 35 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Newark, New Jersey • Philadelphia, Pennsylvania
- Conditions
- Perfusion Pressures, Central Venous Pressure, Cardiac Output, CPR, Cardiac Arrest
- Interventions
- Application of two different sternal weights
- Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 6 Months to 7 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Polycystic Ovary Syndrome, Infertility, Female
- Interventions
- May Health System
- Device
- Lead sponsor
- May Health
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 19
- States / cities
- Encino, California • San Francisco, California • Tampa, Florida + 16 more
- Conditions
- Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia
- Interventions
- Ziftomenib, Cytarabine, Fludarabine
- Drug
- Lead sponsor
- PedAL BCU, LLC
- Other
- Eligibility
- 0 Years to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
- Conditions
- Leukemia
- Interventions
- asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine sulfate
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 16 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 17,463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2023
- U.S. locations
- 214
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
- Conditions
- CAH - Congenital Adrenal Hyperplasia
- Interventions
- NBI-74788
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 3 more
- Conditions
- Glioblastoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
- Radiation · Other · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2030
- U.S. locations
- 230
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 179 more
- Conditions
- Rett Syndrome, RTT
- Interventions
- GWP42003-P
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • La Jolla, California • Aurora, Colorado + 11 more
- Conditions
- Suicide, Engagement, Patient
- Interventions
- The Behavioral Health-Works Suicide Prevention Program for Sexual and Gender Minority Youth
- Behavioral
- Lead sponsor
- Virginia Polytechnic Institute and State University
- Other
- Eligibility
- 14 Years to 19 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Philadelphia, Pennsylvania • Roanoke, Virginia
- Conditions
- Colorectal Neoplasms
- Interventions
- Regorafenib (BAY73-4506)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 62
- States / cities
- Duarte, California • La Jolla, California • Long Beach, California + 53 more
- Conditions
- Advanced Solid Tumors
- Interventions
- oral topotecan (SK&F-104864); lapatinib (GW572016)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis
- Interventions
- Naltrexone Hydrochloride, Placebo Comparator
- Drug · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 3 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- BCNU 80mg/m2, TMZ 200mg/m2, radiation therapy, CCNU, BCNU 150mg/m2, BCNU 200mg/m2, TMZ 150mg/m2 six 6-week cycles, TMZ 150mg/m2 six 8-week cycles
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2018
- U.S. locations
- 92
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Chico, California + 71 more
- Conditions
- Tricuspid Valve Regurgitation
- Interventions
- Transcatheter Tricuspid Valve Replacement
- Device
- Lead sponsor
- inQB8 Medical Technologies, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Thousand Oaks, California • Atlanta, Georgia + 3 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- bryostatin 1, fludarabine phosphate
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2006
- U.S. locations
- 3
- States / cities
- New York, New York • Philadelphia, Pennsylvania • Richmond, Virginia
- Conditions
- Aortic Aneurysm, Thoracic
- Interventions
- GORE TAG® Thoracic Endoprosthesis
- Device
- Lead sponsor
- W.L.Gore & Associates
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 22 more
- Conditions
- HIV Infections, Chronic Pain
- Interventions
- Tai Chi, Health Coaching
- Behavioral
- Lead sponsor
- Temple University
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Iza-bren, Carboplatin, Cisplatin, Pemetrexed, Amivantamab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 661 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 28
- States / cities
- Irvine, California • Orange, California • Edwards, Colorado + 22 more
- Conditions
- Diabetic Retinopathy
- Interventions
- Initiation of treatment of diabetes
- Other
- Lead sponsor
- Temple University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Anemia, Sickle Cell
- Interventions
- ICL670, deferoxamine
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 34
- States / cities
- Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more
- Conditions
- Myasthenia Gravis, Ocular
- Interventions
- Efgartigimod PH20 SC, Placebo PH20 SC
- Combination Product · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Loma Linda, California • Los Angeles, California + 16 more